Evolution of psychopharmacology trial design and analysis: Six decades in the making

Journal of Clinical Psychiatry

Volumn 72, Issue 3, 2011, Pages 331-340

  Leon, Andrew C ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; CHLORPROMAZINE; CLOZAPINE; FLUOXETINE; FLUPHENAZINE; IMIPRAMINE; IPRONIAZID; LITHIUM; LITHIUM CARBONATE; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PHENOBARBITAL; PLACEBO; PROMAZINE; QUETIAPINE; RESERPINE; RISPERIDONE; TETRABENAZINE; THIORIDAZINE; ZIPRASIDONE;

BIPOLAR DISORDER; CASE STUDY; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL OBSERVATION; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); DATA ANALYSIS; DEPRESSION; DRUG APPROVAL; DRUG CONTROL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MECHANISM; DRUG RESEARCH; DRUG RESPONSE; DRUG SAFETY; ELECTROCONVULSIVE THERAPY; FOOD AND DRUG ADMINISTRATION; HUMAN; MAINTENANCE THERAPY; MANIA; MEDICAL ETHICS; METHODOLOGY; OUTCOME ASSESSMENT; PARALLEL DESIGN; PATIENT SELECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; PSYCHOSIS; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; SAMPLE SIZE; SCHIZOPHRENIA; STATISTICAL ANALYSIS; UNITED STATES;

CLINICAL TRIALS AS TOPIC; DATA INTERPRETATION, STATISTICAL; DOUBLE-BLIND METHOD; DRUG EVALUATION; GUIDELINES AS TOPIC; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; MENTAL DISORDERS; PLACEBOS; PSYCHOPHARMACOLOGY; PSYCHOTROPIC DRUGS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SAMPLE SIZE; UNITED STATES;

EID: 79953049243     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.10r06669     Document Type: Review

References (118)

1. US Food and Drug Administration. US Food and Drug Administration: History. 2010. http://www.fda.gov/AboutFDA/WhatWeDo/History/FOrgsHistory/CDER/ CenterforDrugEvaluationandResearchBrochureandChronology/ucm114470.htm#1906. Accessed November 23, 2010.
2. US Food and Drug Administration. Federal Food, Drug, and Cosmetic, As Amended, FDA 93-1051. Washington, DC: Superintendent of Documents, US Government Printing Office; 1993.
3. Medical Research Council. Streptomycin treatment of pulmonary tuberculosis. BMJ. 1948;2(4582):769-782.doi:10.136/bmj.2.4582.769 PubMed
4. Cade JFJ. Lithium salts in the treatment of psychotic excitement. Med J Aust. 1949;2(10):518-520.
5. Delay J, Deniker P, Harl JM. Utilisation en therapeutique psychiatrique dune phenothiazine daction centrale elective (4560-Rp). Presse Med. 1952;60(64):1369.
6. Kuhn V. Uber die Behandlung depressiver zustande mit einem iminodibenzylderival (G 22355). Schweiz Med Wochenschr. 1957; (35-36):1135-1140. PubMed
7. Loomer HP, Saunders JC, Kline NS. A clinical and pharmacodynamic evaluation of iproniazid as a psychic energizer. Psychiatr Res Rep Am Psychiatr Assoc. 1957;8:129-141. PubMed
8. Beecher HK. The powerful placebo. J Am Med Assoc. 1955;159(17): 1602-1606. PubMed
9. Modell W, Houde RW. Factors influencing clinical evaluation of drugs; with special reference to the double-blind technique. J Am Med Assoc. 1958;167(18):2190-2199. PubMed
10. Schou M, Juel-Nielsen N, Stromgren E, et al. The treatment of manic psychoses by the administration of lithium salts. J Neurol Neurosurg Psychiatry. 1954;17(4):250-260.doi:10.136/jnp.17.4.250 PubMed
11. Cutler RP, Monroe JJ, Anderson TE. Effects of tranquilizers upon pathological activity in psychotic patients. AMA Arch Neurol Psychiatry. 1957;78(1):61-68. PubMed
12. Ball JR, Kiloh LG. A controlled trial of imipramine in treatment of depressive states. BMJ. 1959;2(5159):1052-1055.doi:10.136/bmj.2.5159.1052 PubMed
13. Noce RH, Williams DB, Rapaport W. Reserpine (Serpasil) in the management of the mentally ill. J Am Med Assoc. 1955;158(1):11-15. PubMed
14. Barsa JA, Kline NS. Combined reserpine-chlorpromazine therapy in disturbed psychotics. Am J Psychiatry. 1955;111(10):780. PubMed
15. Hollister LE, Krieger GE, Kringel A, et al. Treatment of chronic schizophrenic reactions with reserpine. Ann N Y Acad Sci. 1955;61(1):92-100.doi: 10.1/j.1749-632.195.tb4245.x PubMed
16. Kinross-Wright V. Chlorpromazine and reserpine in the treatment of psychoses. Ann N Y Acad Sci. 1955;61(1):174-182.doi:10.1/j.1749-632.195.tb42464. x PubMed
17. Campden-Main BC, Wegielski Z. The control of deviant behavior in chronically disturbed psychotic patients by the oral administration of reserpine. Ann N Y Acad Sci. 1955;61(1):117-122.doi:10.1/j.1749-632.195.tb42458. x PubMed
18. Goller ES. A controlled trial of reserpine in chronic schizophrenia. J Ment Sci. 1960;106:1408-1412. PubMed
19. Cole JO. Recommendations for reporting studies of psychiatric drugs. Public Health Rep. 1957;72(7):638-645. PubMed
20. Fleming BG, Currie JD. Investigation of a new compound, BW203, and of chlorpromazine in the treatment of psychosis. J Ment Sci. 1958;104(436):749-757. Pub Med
21. Feighner JP, Robins E, Guze SB, et al. Diagnostic criteria for use in psychiatric research. Arch Gen Psychiatry. 1972;26(1):57-63. PubMed
22. Spitzer RL, Endicott J, Robins E. Research Diagnostic Criteria: rationale and reliability. Arch Gen Psychiatry. 1978;35(6):773-782. PubMed
23. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Third Edition. Washington, DC: American Psychiatric Association; 1980.
24. Quitkin FM, McGrath PJ, Stewart JW, et al. Phenelzine and imipramine in mood reactive depressives: further delineation of the syndrome of atypical depression. Arch Gen Psychiatry. 1989;46(9):787-793. PubMed
25. Klein DF, Fink M. Psychiatric reaction patterns to imipramine. Am J Psychiatry. 1962;119:432-438. PubMed
26. Glassman AH, Kantor SJ, Shostak M. Depression, delusions, and drug response. Am J Psychiatry. 1975;132(7):716-719. PubMed
27. Hamilton M. Lectures on the Methodology of Clinical Research. Edinburgh, Scotland: E&S Livingstone; Williams & Wilkins; 1961.
28. Casey JF, Bennett IF, Lindley CJ, et al. Drug therapy in schizophrenia: a controlled study of the relative effectiveness of chlorpromazine, promazine, phenobarbital, and placebo. Arch Gen Psychiatry. 1960;2:210-220. PubMed
29. Ashcroft GW, MacDougall EJ, Barker PA. A comparison of tetrabenazine and chlorpromazine in chronic schizophrenia. J Ment Sci. 1961;107:287-293. PubMed
30. Cole JO. Evaluation of drug treatments in psychiatry. J New Drugs. 1962;2:264-275. PubMed
31. Whittier JR, Klein DF, Levine G, et al. Mepazine (Pacatal): clinical trial with placebo control and psychological study. Psychopharmacologia. 1960;1(4):280-287.doi:10.107/BF040425 PubMed
32. National Institute of Mental Health Psychopharmacology Service Center Collaborative Study Group. Phenothiazine treatment in acute schizophrenia; effectiveness. Arch Gen Psychiatry. 1964;10:246-261. PubMed
33. Baastrup PC, Poulsen JC, Schou M, et al. Prophylactic lithium: double blind discontinuation in manic-depressive and recurrent-depressive disorders. Lancet. 1970;2(7668):326-330.doi:10.1016/S0140-6736(70)92870-9 PubMed
34. Melia PI. Prophylactic lithium: a double-blind trial in recurrent affective disorders. Br J Psychiatry. 1970;116(535):621-624.doi:10.192/bjp.16. 535.621 PubMed
35. Prien RF, Caffey EM Jr, Klett CJ. Prophylactic efficacy of lithium carbonate in manic-depressive illness: report of the Veterans Administration and National Institute of Mental Health collaborative study group. Arch Gen Psychiatry. 1973;28(3):337-341. PubMed
36. Van Putten T, Marder SR. Variable dose studies provide misleading therapeutic windows. J Clin Psychopharmacol. 1986;6(4):249-250.doi:10.1097/ 04714-1986080-025 PubMed
37. Marder SR, Van Putten T, Mintz J, et al. Low- and conventional-dose maintenance therapy with fluphenazine decanoate: two-year outcome. Arch Gen Psychiatry. 1987;44(6):518-521. PubMed
38. Kane JM, Davis JM, Schooler N, et al. A multidose study of haloperidol decanoate in the maintenance treatment of schizophrenia. Am J Psychiatry. 2002;159(4):554-560.doi:10.176/api.ajp.159.4.54 PubMed (Pubitemid 34274936)
39. Van Putten T, Marder SR, Mintz J. A controlled dose comparison of haloperidol in newly admitted schizophrenic patients. Arch Gen Psychiatry. 1990;47(8):754-758. PubMed
40. Chouinard G. A double-blind controlled clinical trial of fluoxetine and amitriptyline in the treatment of outpatients with major depressive disorder. J Clin Psychiatry. 1985;46(3 Pt 2):32-37. PubMed
41. Feighner JP, Cohn JB. Double-blind comparative trials of fluoxetine and doxepin in geriatric patients with major depressive disorder. J Clin Psychiatry. 1985;46(3 Pt 2):20-25. PubMed
42. Fabre LF, Putman HP 3rd. A fixed-dose clinical trial of fluoxetine in out-patients with major depression. J Clin Psychiatry. 1987;48(10):406-408. PubMed
43. Wernicke JF, Dunlop SR, Dornseif BE, et al. Fixed-dose fluoxetine therapy for depression. Psychopharmacol Bull. 1987;23(1):164-168. PubMed
44. Dornseif BE, Dunlop SR, Potvin JH, et al. Effect of dose escalation after low-dose fluoxetine therapy. Psychopharmacol Bull. 1989;25(1):71-79. PubMed
45. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45(9):789-796. PubMed
46. Bowden CL, Calabrese JR, McElroy SL, et al; Divalproex Maintenance Study Group. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Arch Gen Psychiatry. 2000;57(5):481-489.doi:10.101/archpsyc.57.5.481 PubMed
47. Bowden CL, Calabrese JR, Sachs G, et al; Lamictal 606 Study Group. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry. 2003;60(4):392-400.doi:10.101/archpsyc.60.4.392 PubMed
48. Bowden CL, Brugger AM, Swann AC, et al; The Depakote Mania Study Group. Efficacy of divalproex vs lithium and placebo in the treatment of mania. JAMA. 1994;271(12):918-924.doi:10.101/jama.271.12.918 PubMed
49. Calabrese JR, Bowden CL, Sachs GS, et al. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression: Lamictal 602 Study Group. J Clin Psychiatry. 1999;60(2): 79-88.doi:10.408/JCP.v60n0203 PubMed (Pubitemid 29104383)
50. Calabrese JR, Bowden CL, Sachs G, et al; Lamictal 605 Study Group. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry. 2003;64(9):1013-1024.doi:10.408/JCP.v64n0906 PubMed (Pubitemid 37158246)
51. Sachs GS, Thase ME, Otto MW, et al. Rationale, design, and methods of the systematic treatment enhancement program for bipolar disorder (STEP-BD). Biol Psychiatry. 2003;53(11):1028-1042.doi:10.1016/S06-323(03)0165-3 PubMed (Pubitemid 36645233)
52. Nierenberg AA, Sylvia LG, Leon AC, et al; Litmus Study Group. Lithium treatment: moderate dose use study (LiTMUS) for bipolar disorder: rationale and design. Clin Trials. 2009;6(6):637-648.doi:10.17/17407450934739 PubMed
53. Rush AJ, Koran LM, Keller MB, et al. The treatment of chronic depression, part 1: study design and rationale for evaluating the comparative efficacy of sertraline and imipramine as acute, crossover, continuation, and maintenance phase therapies. J Clin Psychiatry. 1998;59(11):589-597.doi:10.408/JCP.v59n106 PubMed (Pubitemid 28555420)
54. Keller MB, Gelenberg AJ, Hirschfeld RM, et al. The treatment of chronic depression, part 2: a double-blind, randomized trial of sertraline and imipramine. J Clin Psychiatry. 1998;59(11):598-607.doi:10.408/JCP.v59n107 PubMed (Pubitemid 28555421)
55. Keller MB, Kocsis JH, Thase ME, et al. Maintenance phase efficacy of sertraline for chronic depression: a randomized controlled trial. JAMA. 1998;280(19):1665-1672.doi:10.101/jama.280.19.165 PubMed (Pubitemid 28532989)
56. Keller MB, McCullough JP, Klein DN, et al. A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. N Engl J Med. 2000;342(20):1462-1470. doi:10.1056/NEJM2051834201 PubMed (Pubitemid 30318269)
57. Klein DN, Santiago NJ, Vivian D, et al. Cognitive-behavioral analysis system of psychotherapy as a maintenance treatment for chronic depression. J Consult Clin Psychol. 2004;72(4):681-688.doi:10.1037/02-06X.72.4.681 PubMed (Pubitemid 38988845)
58. Thase ME, Rush AJ, Howland RH, et al. Double-blind switch study of imipramine or sertraline treatment of antidepressant-resistant chronic depression. Arch Gen Psychiatry. 2002;59(3):233-239.doi:10.101/archpsyc.59.3.23 PubMed (Pubitemid 34212500)
59. Schatzberg AF, Rush AJ, Arnow BA, et al. Chronic depression: medication (nefazodone) or psychotherapy (CBASP) is effective when the other is not. Arch Gen Psychiatry. 2005;62(5):513-520.doi:10.101/archpsyc.62.5.513 PubMed (Pubitemid 40628880)
60. Kocsis JH, Gelenberg AJ, Rothbaum BO, et al; REVAMP Investigators. Cognitive behavioral analysis system of psychotherapy and brief supportive psychotherapy for augmentation of antidepressant nonresponse in chronic depression: the REVAMP Trial. Arch Gen Psychiatry. 2009;66(11):1178-1188.doi:10. 101/archgenpsychiatry.209.14 PubMed
61. Lieberman JA, Stroup TS, McEvoy JP, et al; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209-1223.doi:10.1056/NEJMoa05168 PubMed
62. Lavori PW, Rush AJ, Wisniewski SR, et al. Strengthening clinical effectiveness trials: equipoise-stratified randomization. Biol Psychiatry. 2001;50(10):792-801.doi:10.1016/S06-323(01)0123-9 PubMed (Pubitemid 33086767)
63. Rush AJ, Fava M, Wisniewski SR, et al; STAR*D Investigators Group. Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials. 2004;25(1):119-142.doi:10.1016/S0197-2456(03) 012-0 PubMed (Pubitemid 38230109)
64. Rush AJ, Trivedi MH, Wisniewski SR, et al; STAR*D Study Team. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med. 2006;354(12):1231-1242.doi:10.1056/NEJMoa052963 PubMed
65. Trivedi MH, Fava M, Wisniewski SR, et al; STAR*D Study Team. Medication augmentation after the failure of SSRIs for depression. N Engl J Med. 2006;354(12):1243-1252.doi:10.1056/NEJMoa052964 PubMed
66. Dragalin V. Adaptive designs: terminology and classification. Drug Inf J. 2006;40:425-435. (Pubitemid 44721120)
67. Leon AC. Comparative effectiveness clinical trials in psychiatry: superiority, noninferiority and the role of active comparators [published online ahead of print February 8, 2011]. J Clin Psychiatry. doi:10.408/JCP. 10m06089whi.
68. National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. The Belmont report: ethical principles and guidelines for the protection of human subjects of research. http://ohsr.od.nih.gov/ guidelines/belmont.html. Updated April 18, 1979. Accessed December 20, 2010.
69. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53(282):457-481. doi:10.2307/281868
70. Fleiss JL, Dunner DL, Stallone F, et al. The life table: a method for analyzing longitudinal studies. Arch Gen Psychiatry. 1976;33(1):107-112. PubMed
71. Leon AC, Mallinckrodt CH, Chuang-Stein C, et al. Attrition in randomized controlled clinical trials: methodological issues in psychopharmacology. Biol Psychiatry. 2006;59(11):1001-1005.doi:10.1016/j.biopsych.205.10.020 PubMed (Pubitemid 43870057)
72. Hill AB. Principles of Medical Statistics. 7th ed. New York, NY: Oxford University Press; 1961.
73. Lavori PW. Clinical trials in psychiatry: should protocol deviation censor patient data? Neuropsychopharmacology. 1992;6(1):39-48, discussion 49-63. PubMed
74. Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics. 1982;38(4):963-974.doi:10.2307/2529876 PubMed
75. Jennrich RI, Schluchter MD. Unbalanced repeated-measures models with structured covariance matrices. Biometrics. 1986;42(4):805-820.doi:10.2307/ 2530695 PubMed (Pubitemid 17134900)
76. Gibbons RD, Hedeker D, Waternaux C, et al. Random regression models: a comprehensive approach to the analysis of longitudinal psychiatric data. Psychopharmacol Bull. 1988;24(3):438-443. PubMed
77. Hedeker D, Gibbons RD, Waternaux C, et al. Investigating drug plasma levels and clinical response using random regression models. Psychopharmacol Bull. 1989;25(2):227-231. PubMed
78. Hedeker D, Gibbons RD, Davis JM. Random regression models for multicenter clinical trials data. Psychopharmacol Bull. 1991;27(1):73-77. PubMed
79. Hedeker D. MIXOR: a Fortran program for mixed-effects ordinal probit and logistic regression. Technical Report, Prevention Research Center. Chicago, IL: School of Public Health, University of Illinois at Chicago; 1992.
80. Hedeker D. MIXREG: a Fortran program for mixed-effects linear regression with autocorrelated errors. Technical Report, Prevention Research Center. Chicago, IL: School of Public Health, University of Illinois at Chicago; 1992.
81. Hedeker D, Gibbons RD. MIXREG: a computer program for mixed-effects regression analysis with autocorrelated errors. Comput Methods Programs Biomed. 1996;49(3):229-252.doi:10.1016/0169-2607(96)01723-3 PubMed (Pubitemid 26171928)
82. Hedeker D, Gibbons RD. MIXOR: a computer program for mixed-effects ordinal regression analysis. Comput Methods Programs Biomed. 1996;49(2):157-176.doi:10.1016/0169-2607(96)01720-8 PubMed (Pubitemid 26155247)
83. Gibbons RD, Hedeker D, Elkin I, et al. Some conceptual and statistical issues in analysis of longitudinal psychiatric data: application to the NIMH treatment of Depression Collaborative Research Program dataset. Arch Gen Psychiatry. 1993;50(9):739-750. PubMed
84. Elkin I, Shea MT, Watkins JT, et al. National Institute of Mental Health Treatment of Depression Collaborative Research Program: general effectiveness of treatments. Arch Gen Psychiatry. 1989;46(11):971-982, discussion 983. PubMed
85. Fawcett J, Epstein P, Fiester SJ, et al; NIMH Treatment of Depression Collaborative Research Program. Clinical management-imipramine/placebo administration manual. Psychopharmacol Bull. 1987;23(2): 309-324. PubMed
86. Cohen J. Statistical Power Analysis for the Behavioral Sciences. New York, NY: Academic Press; 1969.
87. Overall JE, Dalal SN. Design of experiments to maximize power relative to cost. Psychol Bull. 1965;64(5):339-350.doi:10.1037/h02527 PubMed
88. Kraemer HC, Kupfer DJ. Size of treatment effects and their importance to clinical research and practice. Biol Psychiatry. 2006;59(11):990-996.doi:10. 1016/j.biopsych.205.09.014 PubMed (Pubitemid 43849650)
89. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23(1):56-62.doi:10.136/jnp.23.1.56 PubMed
90. Overall JE. The Brief Psychiatric Rating Scale. Psychopharmacol Bull. 1988;24:97-99.
91. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134(4):382-389.doi:10.192/bjp.134.4.382 PubMed (Pubitemid 9136500)
92. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261-276. PubMed
93. Shear MK, Brown TA, Barlow DH, et al. Multicenter collaborative Panic Disorder Severity Scale. Am J Psychiatry. 1997;154(11):1571-1575. PubMed
94. Rush AJ, Gullion CM, Basco MR, et al. The Inventory of Depressive Symptomatology (IDS): psychometric properties. Psychol Med. 1996;26(3):477-486. doi:10.1017/S0329170358 PubMed (Pubitemid 26142491)
95. Young RC, Biggs JT, Ziegler VE, et al. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133(5):429-435.doi: 10.192/bjp.13.5.429 PubMed (Pubitemid 9006756)
96. Blake DD, Weathers FW, Nagy LM, et al. The development of a Clinician-Administered PTSD Scale. J Trauma Stress. 1995;8(1):75-90.doi:10.102/ jts.249080106 PubMed
97. Guy W. ECDEU Assessment Manual For Psychopharmacology. Rockville, MD: Department of Health, Education, and Welfare; 1976.
98. Rush AJ, First MB, Blacker D, American Psychiatric Association. Task Force for the Handbook of Psychiatric Measures. Handbook of Psychiatric Measures. 2nd ed. Washington, DC: American Psychiatric Publishing.; 2008.
99. Levine J, Schiele BC, Bouthilet L. Principles and Problems in Establishing the Efficacy of Psychotropic Agents. Chevy Chase, MD: National Institute of Mental Health; 1971.
100. Prien RF, Robinson DS, National Institute of Mental Health, American College of Neuropsychopharmacology. Clinical Evaluation of Psychotropic Drugs: Principles and Guidelines. New York, NY: Raven Press; 1994.
101. Food and Drug Administration. General Considerations for the Clinical Evaluation of Drugs. 1977. http://www.fda.gov/downloads/ScienceResearch/ SpecialTopics/WomensHealthResearch/UCM131196.pdf. Accessed January 28, 2011.
102. Food and Drug Administration. Guidelines for the Clinical Evaluation of Antidepressant Drugs; 1977. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm071299.pdf. Updated February 1997. Accessed December 20, 2010.
103. Food and Drug Administration. Guidelines for the Clinical Evaluation of Antianxiety Drugs 1977. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm071295.pdf. Updated February 1997. Accessed December 20, 2010.
104. Food and Drug Administration Conference on Harmonisation I. E9 - Statistical Principles for Clinical Trials 1998. http://www.fda.gov/downloads/ Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm073137.pdf. Updated September 1998. Accessed December 20, 2010.
105. Food and Drug Administration Conference on Harmonization I. E10 - Choice of Control Group and Related Issues in Clinical Trials 2001. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/ucm073139.pdf. Updated May 2001. Accessed December 20, 2010.
106. Food and Drug Administration. Non-Inferiority Clinical Trials: Draft Guidance for Industry; 2010. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM202140.pdf. Updated March 2010. Accessed December 20, 2010.
107. Food and Drug Administration. Adaptive Design Clinical Trials for Drugs and Biologics: Draft Guidance for Industry; 2010. http://www.fda.gov/downloads/ Drugs/guidancecomplianceregulatoryinformation/guidances/ucm201790.pdf. Updated February 2010. Accessed December 20, 2010.
108. Begg C, Cho M, Eastwood S, et al. Improving the quality of reporting of randomized controlled trials: the CONSORT statement. JAMA. 1996;276(8):637-639. doi:10.101/jama.276.8.637 PubMed (Pubitemid 26278070)
109. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet. 2001;357(9263):1191-1194.doi:10.1016/S0140-6736(0) 0437-3 PubMed (Pubitemid 32378696)
110. Schulz KF, Altman DG, Moher DCONSORT; CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. PLoS Med. 2010;7(3):e1000251.doi:10.1371/journal.pmed.10251 PubMed
111. Moher D, Hopewell S, Schulz KF, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c869. PubMed
112. Food and Drug Administration. (2004). Briefing document for February 2, 2004 Meeting of Psychopharmacological Drugs Advisory Committee (PDAC) and Pediatric Subcommittee of the Anti-Infective Drugs Advisory Committee (Peds AC). http://www.fda.gov/ohrms/dockets/ac/04/briefing/2004-4065b1-04-Tab02-Laughren- Jan5.pdf. Accessed January 28, 2011.
113. Walsh BT, Seidman SN, Sysko R, et al. Placebo response in studies of major depression: variable, substantial, and growing. JAMA. 2002;287(14):1840- 1847.doi:10.101/jama.287.14.1840 PubMed (Pubitemid 34303629)
114. Kraemer HC. To increase power in randomized clinical trials without increasing sample size. Psychopharmacol Bull. 1991;27(3): 217-224. PubMed
115. Leon AC, Marzuk PM, Portera L. More reliable outcome measures can reduce sample size requirements. Arch Gen Psychiatry. 1995; 52(10):867-871. PubMed
116. Kobak KA, Kane JM, Thase ME, et al. Why do clinical trials fail? the problem of measurement error in clinical trials: time to test new paradigms? J Clin Psychopharmacol. 2007;27(1):1-5.doi:10.1097/JCP.0b013e31802eb4b7 PubMed (Pubitemid 46105756)
117. Leon AC. Two clinical trial designs to examine personalized treatments for psychiatric disorders [article published online ahead of print July 13, 2010]. J Clin Psychiatry. 2010. PubMed
118. Kraemer HC, Wilson GT, Fairburn CG, et al. Mediators and moderators of treatment effects in randomized clinical trials. Arch Gen Psychiatry. 2002;59(10):877-883.